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Measles virus (MV), a member of the Morbillivirus
genus in the Paramyxoviridae family, is an enveloped
virus with a nonsegmented negative-strand RNA ge-
nome and infects humans and nonhuman primates (Grif-
fin, 2001). Despite the availability of vaccines, MV re-
mains a major cause of childhood mortality, claiming
roughly one million lives a year worldwide. The transient
immunosuppression that accompanies and follows mea-
sles renders the patients susceptible to secondary in-
fections accounting for most of measles-related compli-
cations and deaths. MV also causes postinfectious en-
cephalitis, and in rare instances, subacute sclerosing
panencephalitis, a persistent infection in the central ner-
vous system. This review is concerned with the identifi-
cation of a new MV receptor and its implication for
understanding the pathology and pathogenesis of MV
infection.
MV was first isolated in primary human kidney cells
inoculated with the blood and throat washings of a child
with measles (Enders and Peebles, 1954). This first iso-
late, the Edmonston strain, was subsequently adapted to
chicken embryo fibroblasts and became the progenitor
for currently used attenuated vaccines. The Edmonston
strain also grows well in continuous cell lines and has
become the most extensively studied MV strain in labo-
ratories. Vero cells, an African green monkey kidney cell
line, had been commonly used for MV isolation until a
decade ago, but several blind passages were usually
required before virus propagation and development of
cytopathic effect (CPE). Kobune et al. (1990) reported that
an Epstein–Barr virus (EBV)-transformed marmoset B cell
line B95-8 and its adherent subline B95a were highly
sensitive to MV. Furthermore, they showed that MV
strains isolated in B95a cells, but not Vero cell-isolated
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al., 1990, 1996). Thus, the use of B95a is currently rec-
ommended for MV isolation from clinical specimens
(World Health Organization, 2001). Subsequently, other
human B cell lines have been also successfully em-
ployed for MV isolation (Schneider-Schaulies et al.,
1995b; Lecouturier et al., 1996).
In 1993, human CD46 (also known as membrane co-
factor protein) was identified as a cellular receptor for
the Edmonston and Halle strains of MV (Dorig et al.,
1993; Naniche et al., 1993a). CD46 is a complement
regulatory molecule and is expressed on all nucleated
cells in humans. The Edmonston and Vero cell isolated
strains are capable of infecting any CD46 primate cell
lines. On the other hand, B cell isolated strains grow in a
restricted number of B and T cell lines and phytohemag-
glutinin-stimulated peripheral blood mononuclear cells
(PBMC), but not in other CD46 cell lines (Schneider-
Schaulies et al., 1995b; Lecouturier et al., 1996; Hsu et al.,
1998; Tanaka et al., 1998; Tatsuo et al., 2000a). Further-
more, the Edmonston strain causes hemadsorption with
monkey red blood cells (which express CD46, unlike
human red blood cells) and CD46 downregulation from
the surface of the infected cells, whereas B cell isolated
strains do not (Saito et al., 1992; Naniche et al., 1993b;
Schneider-Schaulies et al., 1995a; Lecouturier et al.,
1996).
MV has two envelope glycoproteins, the hemaggluti-
nin (H) and fusion (F) protein, mediating receptor binding
and membrane fusion, respectively (Griffin, 2001). Sev-
eral studies provided evidence that the H protein of the
Edmonston strain, but not of B cell isolated strains,
interacts with CD46 (Lecouturier et al., 1996; Hsu et al.,
1998; Tanaka et al., 1998), suggesting the presence of
another receptor for B cell isolated strains. Others, how-
ever, argued that B cell isolated strains can enter cells
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IDENTIFICATION OF A NEW CELLULAR
RECEPTOR FOR MV
To determine the mechanism underlying the different
cell tropism of the Edmonston and B cell isolated strains,
we utilized the pseudotype system based on the recom-
binant vesicular stomatitis virus (VSV) containing the
green fluorescent protein as a reporter (Takada et al.,
1997). Since this recombinant VSV lacks the gene encod-
ing the G envelope protein, it can only enter cells using
envelope proteins provided in trans. However subse-
quent intracellular steps progress as part of the VSV
replication cycle. Our study using this system demon-
strated that the difference in cell tropism between the
MV strains was largely determined by viral entry (Tatsuo
et al., 2000a), suggesting that the receptor molecule that
enables B cell isolated MV strains to enter cells is
present only on some lymphoid cell lines.
We attempted to identify this putative receptor by func-
tional expression cloning in which the nonsusceptible
human kidney cell line 293T was transfected with a
cDNA library of B95a cells and then screened with the
VSV pseudotype bearing the H protein of a B cell isolated
MV strain and F protein of the Edmonston strain (Tatsuo
et al., 2000b). A single clone was obtained that could
make the transfected 293T cells highly susceptible to the
pseudotype. This marmoset cDNA clone had a high level
of similarity to the human signaling lymphocyte activa-
tion molecule (SLAM; also known as CD150) gene, sug-
gesting that human SLAM, a membrane glycoprotein
involved in lymphocyte activation (Cocks et al., 1995), is
a cellular receptor for this and other B cell isolated MV
strains that cannot use CD46 as a receptor.
Further experiments showed that expression of human
SLAM conferred on nonsusceptible cell lines the abilities
to bind MV, support MV entry and replication, and de-
velop CPE, when several B cell isolated strains as well
as the Edmonston strain were tested. In addition, MV
infection was inhibited by anti-SLAM antibody. These
results established that SLAM is a cellular receptor for
MV (Tatsuo et al., 2000b).
Since rodent cells such as Chinese hamster ovary
(CHO) cells that do not express CD46 are able to support
MV growth after expression of human SLAM, CD46 is not
required for SLAM to act as a receptor. Importantly, the
Edmonston strain can use both SLAM and CD46 as
receptors. MV strains isolated in PBMC have been re-
ported to use CD46 as a receptor (Manchester et al.,
2000), but they are also able to use SLAM as a receptor
(Tatsuo et al., 2000b). Since these PBMC isolates pro-
duce CPE in SLAM-expressing CHO cells, but not in
CD46-expressing CHO cells, SLAM may serve better as
a receptor for these strains than CD46. Expression of
SLAM on various cell lines correlates with their suscep-
tibility to B cell isolated MV strains. B95a cells express a
high level of SLAM, which may explain why they have
been useful in isolating MV from clinical specimens.
Shortly afterward, two other groups confirmed all our
findings by using different approaches (Erlenhoefer et
al., 2001; Hsu et al., 2001).
THE PRINCIPAL MV RECEPTOR IN THE BODY
Viruses isolated in cultured cells may not be represen-
tative of those in vivo because of in vitro selection and/or
adaptation. To ascertain in vivo relevance of SLAM as an
MV receptor, we inoculated human SLAM-expressing
CHO cells with throat swabs from measles patients. The
cells developed CPE at 36 h after inoculation with throat
swabs, and syncytia formed were strongly stained with
anti-MV antibody (Tatsuo et al., 2000b), indicating that
SLAM can act as a receptor for MV in the body.
No MV strains have been found that cannot use SLAM
as a receptor, whereas only the Edmonston and some
other strains can use, besides SLAM, CD46 as a recep-
tor. Furthermore, MV isolates are more rapidly and effi-
ciently obtained from clinical specimens, in B95a cells
than in Vero cells (Kobune et al., 1990; Griffin, 2001).
These observations suggest that the majority of MV in
the body use SLAM as a receptor, and only a small
minority may also use CD46. We titrated on SLAM-pos-
itive and -negative cells the viruses present on throat
swabs from several measles patients. The results
showed that most samples produced numerous plaques
on SLAM-expressing Vero cells, but none (less than the
detection limit) on Vero cells (Ono et al., 2001a). Thus, the
great majority of MV in the bodies of measles patients
use SLAM but not CD46 as a receptor.
The use of CD46 by someMV strains may be considered
an in vitro adaptation rather than an in vivo property of those
strains. Such an adaptation can occur easily because a
single amino acid substitution at position 481 of the H
protein to tyrosine or at position 546 to glycine enables B
cell isolated MV strains to interact with CD46 (Shibahara et
al., 1994; Bartz et al., 1996; Lecouturier et al., 1996; Rima et
al., 1997; Hsu et al., 1998; Xie et al., 1999). Therefore, MV
isolation and passage in SLAM-negative cells such as
human kidney cells and Vero cells may have selected the
viruses capable of using CD46 as a receptor. In fact, glycine
at position 546 of the H protein was shown to correlate with
the passage history of MV isolates in Vero cells (Woelk et
al., 2001). Likewise, the vaccine strains must have adapted
to chicken embryo fibroblasts by using a molecule present
on them. Figure 1 summarizes our model of the receptor
usage of various MV strains.
On the other hand, the use of CD46 as a receptor
appears to be more advantageous for MV because dis-
tribution of CD46 is ubiquitous, unlike that of SLAM.
Thus, some mechanism must operate in vivo to suppress
the growth of the viruses capable of using CD46 as a
receptor. One possible explanation would be that those
viruses downregulate CD46 from infected cells, which
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are then subject to complement-mediated lysis and are
eliminated (Schnorr et al., 1995).
There have been reports that the viruses grow in Vero
cells even though their H proteins do not interact with
CD46. The recombinant Edmonston MV expressing the
H protein of the B cell isolated WTF strain spread in Vero
cells, although the parental WTF strain did not (Johnston
et al., 1999). A PBMC-isolated strain, which uses SLAM
but not CD46 as a receptor, was successfully adapted to
Vero cells without the acquisition of the ability to interact
with CD46 (Kouomou and Wild, 2002). Another study
reported that there was no sequence difference in the H
gene between MV strains isolated in B95a and in Vero
cells from the same measles patient (Takeuchi et al.,
2000). In all these cases, the viruses appear to enter Vero
cells independently of SLAM and CD46. By using the
recombinant MV expressing the green fluorescent pro-
tein, we have demonstrated that a B cell isolated MV
strain can infect SLAM-negative cells with 2 to 3 log
lower efficiency than it does SLAM-positive cells (Hashi-
moto et al., 2002). The infection is probably mediated by
an as yet unidentified receptor other than SLAM and
CD46. Vero cells, which lack the type 1 interferon system,
may allow efficient MV replication after some adaptation
of the virus, even if entry is inefficient.
STRUCTURE AND FUNCTION OF SLAM
Human SLAM was originally identified as a cell-sur-
face glycoprotein of a relative mass of 70 kDa found on
activated B cells and T cells (Sidorenko and Clark, 1993;
Cocks et al., 1995). It is a member of the immunoglobulin
superfamily and has two extracellular domains, V and C2
(Fig. 2). Its cytoplasmic domain contains three tyrosine
residues that are surrounded by SH2 domain-binding
sequences. In fact, SLAM has been shown to associate
intracellularly with SH2 domain-containing molecules
such as the SLAM-associated protein (SAP; also known
as SH2D1A), protein tyrosine phosphatase SHP-2, and
inositol phosphatase SHIP (Sayos et al., 1998; Shlapat-
ska et al., 2001). The SLAM gene is located at the human
chromosome 1q22-q23.
SLAM is reported to be a self-ligand (Mavaddat et al.,
2000). Engagement of SLAM by a monoclonal antibody
A12 leads to IL-2-independent T cell expansion and
IFN- production by activated T cells, including Th2 cells
(Cocks et al., 1995; Aversa et al., 1997). Ligation of SLAM
with a monoclonal antibody IPO-3 augments B cell pro-
liferation induced by anti-CD40 and IL-4 (Sidorenko and
Clark, 1993). Soluble and membrane-bound forms of
SLAM induce proliferation and immunoglobulin synthe-
sis by activated human B cells (Punnonen et al., 1997).
SLAM signaling also augments CD95-mediated apopto-
sis of B cells (Mikhalap et al., 1999). However, a recent
study showed that SLAM signaling might be involved in
inhibiting IFN- production by T cells, arguing that the
effect of A12 was not agonistic but inhibitory on SLAM
signaling (Latour et al., 2001). The study also proposed a
model for the signal transduction via SLAM in T cells,
which involves the SAP, protein tyrosine kinase Fyn,
SHIP, and several other adaptor molecules. Mutations in
the human SAP gene cause X-linked lymphoproliferative
disease (Sayos et al., 1998), patients with which show
FIG. 2. Structure of human SLAM. SLAM contains two highly glyco-
sylated immunoglobulin superfamily domains, V and C2. The cytoplas-
mic tail of SLAM has tyrosine residues surrounded by SH2-domain-
binding sequences, to which SAP binds in phosphotyrosine-indepen-
dent and -dependent fashions.
FIG. 1. Receptor usage of MV strains. Wild-type viruses mainly use
SLAM as a cellular receptor. Strains obtained through in vitro selection/
adaptation are also able to use other receptors, besides SLAM.
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progressive lymphocyte expansions after primary EBV
infection. SAP knockout mice also exhibit increased
IFN- production and defect in Th2 development (Wu et
al., 2001).
Mouse SLAM has a similar structure (about 60% iden-
tity at the amino acid level) and function to the human
counterpart (Castro et al., 1999), but cannot act as an MV
receptor (Ono et al., 2001b), partly explaining the inability
of mice to support MV infection. The V domain of human
SLAM fused to various transmembrane proteins was
able to act as an MV receptor, whereas a chimeric
human/mouse SLAM containing the mouse V domain in
place of the human V domain could not function as a
receptor. The cytoplasmic domain of SLAM was not
necessary for the receptor function. Furthermore, the
soluble molecules possessing the V domain of human
SLAM bound to cells expressing the MV H protein, but
not to cells expressing irrelevant envelope proteins (Ono
et al., 2001b). Thus, the V domain of human SLAM is
necessary and sufficient to interact with the MV H pro-
tein and allow MV entry. Similar to other viral receptors
belonging to immunoglobulin superfamily, the N-terminal
(membrane-distal) domain of SLAM is responsible for
the interaction with the virus.
DISTRIDUTION OF SLAM
Human SLAM is constitutively expressed on immature
thymocytes, CD45ROhigh memory T cells, and a propor-
tion of B cells, and rapidly induced on all T and B cells
following activation (Sidorenko and Clark, 1993; Cocks et
al., 1995; Aversa et al., 1997). SLAM is differentially ex-
pressed in CD4 T cells. Whereas high levels of SLAM are
found in Th1 cells, only small amounts are detectable in
Th2 cells (Hamalainen et al., 2000). Among cultured cells,
it is expressed on antigen-specific T cell clones and
EBV-transformed B cell lines, but not on most T cell and
monocyte/macrophage lines. SLAM is not detected on
monocytes, granulocytes, and cells from nonlymphoid
organs (Sidorenko and Clark, 1993; Cocks et al., 1995;
Aversa et al., 1997).
Although such tissue distribution of SLAM is consis-
tent with lymphotropism of MV (Kobune et al., 1996;
McChesney et al., 1997; Griffin, 2001), infection of mono-
cytes, another major target in vivo, cannot be explained.
We found that although monocytes freshly isolated from
PBMC do not express SLAM, its expression is readily
induced after stimulation with mitogens or even with MV
particles alone (Minagawa et al., 2001). Furthermore,
mature dendritic cells, but not immature dendritic cells,
also express SLAM (Polacino et al., 1996; Bleharski et al.,
2001; Kruse et al., 2001; Ohgimoto et al., 2001). Anti-
SLAM antibody blocks infection of activated monocytes
and mature dendritic cells with a B cell isolated MV
strain (Minagawa et al., 2001; Y. Yanagi et al., unpub-
lished observation). Thus, MV infection of lymphocytes,
monocytes/macrophages, and dendritic cells must be
mediated by SLAM.
It is generally thought that MV enters through the
respiratory route, initially infecting respiratory epithelial
cells, and then spread to lymphoid tissues (Griffin, 2001).
We, however, suspect that initial targets of MV in the
respiratory tract are SLAM-positive cells of the immune
system rather than epithelial cells, since the latter cells
are not shown to express SLAM. Furthermore, a recent
study showed that the Edmonston strain, which can use
CD46 as a receptor, does not efficiently enter respiratory
epithelial cells through the apical surface where CD46 is
abundantly expressed (Sinn et al., 2002).
There have been reports that tumors regressed in
children with Burkitt’s lymphoma and with Hodgkin’s dis-
ease after measles (Bluming and Ziegler, 1971; Taqi et
al., 1981). These observations may be understood in light
of SLAM as an MV receptor. It has been known that
EBV-transformed B cells express high levels of SLAM
(Aversa et al., 1997), presumably explaining regression of
Burkitt’s lymphoma. Probably, the tumor cells of the
cases with Hodgkin’s disease would also have ex-
pressed SLAM and then been destroyed by MV. These
examples suggest that the use of MV for oncolytic ther-
apy (Grote et al., 2001) may be readily applicable to
SLAM-expressing tumors.
SLAM AND MV-INDUCED IMMUNOSUPPRESSION
Infection and subsequent destruction of SLAM cells
may explain severe immunosuppression and lymphope-
nia characteristic of measles. Killing activated lympho-
cytes and monocytes and mature dendritic cells will lead
to impairment of innate immunity as well as that of
acquired immunity. Furthermore, the finding that memory
T cells and Th1 cells express high levels of SLAM nicely
explains why patients with measles show suppressed
delayed type hypersensitivity responses such as the
tuberculin skin test and exhibit the Th2 polarization in
cytokine responses during and after measles (Griffin,
2001).
Mere binding of MV particles or envelope proteins to
the V domain of SLAM on the cell surface may affect, by
mimicking the natural ligand, the signals induced
through SLAM, thereby impairing lymphocyte activation
(Yanagi et al., 1992). Although the interaction of the H
protein with SLAM results in its downregulation from the
cell surface (Erlenhoefer et al., 2001; Tanaka et al., 2002),
there is presently no evidence that modulation of SLAM
signaling indeed occurs. Schneider-Schaulies and col-
leagues have shown that the cell surface contact of MV
glycoproteins induces inhibition of lymphocyte prolifera-
tion in vitro (Schlender et al., 1996), where Akt kinase
activation is disrupted (Avota et al., 2001). Their data
indicate that both the H and the F proteins are required
for the inhibition of lymphocyte proliferation and that the
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cleavage of the F protein but not membrane fusion is
involved (Weidmann et al., 2000). They have not identified
the cell-surface molecule(s) on lymphocytes that interact
with MV envelope proteins, but reported that it is not
SLAM (Erlenhoefer et al., 2001).
Other mechanisms of MV-induced immunosuppres-
sion have also been proposed. CD46 cross-linking by
MV inhibits IL-12 production by monocytes (Karp et al.,
1996), and suppression of IL-12 production was indeed
observed in measles patients, supporting the role of
MV-CD46 interaction (Atabani et al., 2001). However, the
in vivo significance of the finding remains to be deter-
mined because the majority of wild-type MV do not seem
to interact with CD46. Recently, the nucleoprotein of MV
was shown to have an immunosuppressive activity
(Marie et al., 2001). It binds to the Fc receptor on
antigen-presenting cells and impairs their ability to stim-
ulate antigen-specific T cell proliferation. All these mech-
anisms are not necessarily mutually exclusive and may
operate together to cause the severe immunosuppres-
sion induced by MV.
SLAM AS MORBILLIVIRUS RECEPTORS
The Morbillivirus genus comprises MV, canine distem-
per virus (CDV), rinderpest virus (RPV), peste des petits
ruminants virus, and emerging morbilliviruses of aquatic
mammals (phocine, dolphin, and porpoise distemper vi-
ruses). All these viruses are highly contagious patho-
gens that cause devastating diseases in respective host
species accompanied by severe immunosuppression
and lymphopenia. It has been reported that the marmo-
set B cell line B95a is a sensitive host for CDV and RPV
as it is for MV (Kobune et al., 1991; Kai et al., 1993).
The common tropism and pathology of these viruses
suggested to us that SLAM might also act as receptors
for morbilliviruses other than MV. We isolated cDNAs
encoding canine and bovine SLAMs from PBMC of re-
spective species and demonstrated that CDV and RPV,
respectively, use canine and bovine SLAMs as cellular
receptors (Tatsuo et al., 2001). Vaccine strains of CDV
and RPV, which had been passaged on SLAM-negative
cells, were found to use alternative receptors besides
SLAM, probably because of in vitro adaptation. Further-
more, we found that the majority of MV, CDV, and RPV
strains examined could use any of human, canine, and
bovine SLAMs as receptors, albeit with varying degrees
of efficiency, suggesting that the structure required for the
interaction with morbillivirus envelope proteins may be well
conserved among SLAMs of many different species.
Phylogenetic analysis indicates that CDV is the most
distantly related to MV and RPV among morbilliviruses.
Thus, the finding that the three morbilliviruses use
SLAMs as cellular receptors suggests that this property
has been maintained from the ancestral morbillivirus. We
suspect that most, if not all, members of morbilliviruses
use SLAMs of their respective host species as cellular
receptors. Morbilliviruses have been grouped together
by their sequence relatedness and lack of neuramini-
dase activity. Now the use of SLAM as a cellular receptor
may be included in their characteristic properties.
CONCLUSIONS
We cannot exclude the possibility that there are still
other molecules, including CD46, acting in vivo as a
cellular receptor for MV. For example, MV infections of
epithelial, endothelial, and neuronal cells reported in the
literature (Griffin, 2001) may be explained by an alterna-
tive receptor(s). Nevertheless, SLAM appears to be the
principal receptor for MV (and morbilliviruses in general),
accounting for most of MV pathology and pathogenesis.
The Edmonston strain has dominated MV research in the
past. Since it may not be representative of MV in the
body, we should instead use B cell isolated strains for
studying the pathogenesis of MV infection. In this regard,
a recently developed reverse genetics system based on
a wild-type MV strain will prove most fruitful (Takeda et
al., 2000). Furthermore, SLAM transgenic mouse, to-
gether with available CD46 transgenic models (Mrkic et
al., 1998; Oldstone et al., 1999), will serve as a useful
animal model to investigate MV pathogenesis and host
immune responses.
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